Neoris

What Neoris does

Neoris is a Paris-headquartered private platform company founded in 2017 around the FLAAK (Femto Laser Aesthetic Annular Keratopigmentation) technique, a surgical method for permanent eye color change developed by Dr. Francis Ferrari in 2013. The company does not perform surgeries itself; instead it connects prospective patients with a network of 40+ vetted ophthalmological surgery clinics across France and the United States, and supplies the proprietary NEORIS pigment line and patented surgical instrumentation required for the procedure. Its core technology asset is the FLAAK protocol combined with a 16-shade corneal-compatible pigment portfolio, both of which are tied to surgeon training and certification delivered by Dr. Ferrari.

Neoris monetizes the FLAAK ecosystem through three primary streams: per-procedure fees retained by partner clinics (procedure pricing of $5,700-$12,000), sales of NEORIS pigments and surgical instrument kits to trained surgeons, and surgeon training and certification packages that include instrumentation, dye, and femtosecond laser adjustments. The platform combines a direct-to-consumer digital front end (multilingual website, online eye color simulator, before/after galleries, clinic finder) with a B2B channel that onboards and certifies new ophthalmic surgeons. Neoris-affiliated surgeons represent approximately 90% of all FLAAK procedures performed globally, and the website attracts hundreds of thousands of annual visits. The company remains founder-owned and operationally lean, with 11 employees and no external funding disclosed.

Key strategic and regulatory characteristics include the 2022 introduction of a reversibility technique, the 2023 launch of next-generation colorants for improved long-term stability, and a formal regulatory ruling excluding NEORIS aesthetic pigments from CE marking. The business is structurally a two-sided medical platform constrained by a narrow regulatory perimeter, a single key-opinion-leader dependence on Dr. Ferrari, and a luxury cosmetic procedure market susceptible to discretionary spending cycles.

Name

Neoris

Legal name

Neoris

Website

https://neoris-eyes.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Neoris is a Paris-based platform connecting prospective patients with partner clinics that perform FLAAK keratopigmentation, a patented femtosecond laser surgery for permanent eye color change invented by Dr. Ferrari. It monetizes via pigment sales, surgeon training, and a multilingual clinic finder serving 40+ clinics across France and the United States.

Ownership category

akta.pro rank

Product category

Cosmetic Eye Surgery

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Synthetic Dye and Pigment Manufacturing (325130)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

akta.pro secondary industries

Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG), Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

Keywords

• Cosmetic eye surgery
• Keratopigmentation procedure
• Permanent eye color change
• Corneal pigmentation pigments
• Ophthalmic surgery network

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Keratopigmentation Surgery Fees: Neoris connects patients with partner clinics that perform the FLAAK keratopigmentation procedure. The surgery costs between $5,700 and $12,000 depending on clinic, country, and services included (evaluation, surgery, post-operative follow-up).
2. Pigment/Colorant Sales: NEORIS develops and supplies corneal-compatible pigments for the keratopigmentation procedure to partner clinics.
3. Surgeon Training and Certification: Ophthalmic surgeons can access training materials, videos, documentation, and certification through Neoris to perform the FLAAK procedure. The package includes surgical instrumentation, dye, and femtosecond laser adjustments.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Neoris operates the FLAAK (Femto Laser Aesthetic Annular Keratopigmentation) platform, enabling permanent eye color change via a femtosecond-laser surgical technique. The company connects patients with a network of trained ophthalmic surgeons, supplies proprietary NEORIS corneal-compatible pigments in 16+ shades, and offers a reversibility method. It also certifies and trains surgeons, providing patented surgical instrumentation and pigment packages to partner clinics.

Product overview

Neoris operates as a medical platform offering FLAAK (Femto Laser Aesthetic Annular Keratopigmentation), a permanent eye color change procedure using femtosecond laser technology to insert biocompatible corneal pigments. The company connects patients with a network of trained surgeons through its platform, provides an online eye color simulator for consultation, and offers 16+ pigment color options including Ocean, Pistachio, Emerald Green, and others. The FLAAK procedure is reversible since 2022 and was first performed in 2013 by Dr. Francis Ferrari, representing approximately 90% of all keratopigmentation procedures performed worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• FLAAK Keratopigmentation Procedure Permanent outpatient eye color change surgery using a femtosecond laser to create micro-tunnels in the cornea, into which NEORIS biocompatible pigments are inserted under local anesthesia; takes 30-45 minutes for both eyes, no hospitalization required. Offered to adults seeking permanent cosmetic eye color change via Neoris partner clinics.
• NEORIS Corneal-Compatible Pigments Biocompatible pigment suspensions available in 16+ exclusive shades (e.g., Ocean, Pistachio, Emerald Green, Riviera Blue, Honey Gold, Lagoon, Moon Grey, Jade, Sahara, Silk Blue, Water Green, Olive, Pacific, Aqua Green, Hazelnut, Snow White) sold to partner ophthalmic surgery clinics for use in the FLAAK procedure.
• Surgeon Training and Certification Program Training and certification package for ophthalmic surgeons including video training, documentation, patented surgical instrumentation, NEORIS pigments, femtosecond laser adjustments, and listing on the Neoris clinic finder for patient referrals. Targeted at ophthalmic surgeons wanting to add keratopigmentation to their practice.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Partner Ophthalmic SurgeonscoreChannel Partner/ Reseller/ DistributorOphthalmic surgeons who perform keratopigmentation procedures using the FLAAK technique. Surgeons are carefully trained by technique inventor Dr. Ferrari, must follow precise medical protocols, hold compulsory insurance, and are listed on the Neoris platform for patient access. The network represents nearly 90% of global FLAAK procedures.
• Dr. Francis FerraricoreStrategic or Co-development PartnerOphthalmic surgeon and inventor of the FLAAK keratopigmentation technique. Graduated from the prestigious University Clinic of Tübingen (Germany) and specialized in refractive surgery. Developed the FLAAK technique in 2013 and continues to train and certify surgeons in the method.
• Bubbly and Single QuoteminorOthersWebsite development agencies credited for the creation of the neoris-eyes.com website. Bubbly (bubbly.fr) and Single Quote (singlequote.net) designed and developed the multilingual platform.
• OVH SASminorOthersWebsite hosting provider. OVH SAS is a French cloud computing company that hosts the neoris-eyes.com website. Located at 2 rue Kellermann, 59100 Roubaix, France.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Ziemer Ophthalmic Systems: Swiss manufacturer of femtosecond laser systems used in refractive and corneal surgery, including the FEMTO LDV platform. Directly comparable to Neoris as a provider of the femtosecond laser hardware on which the FLAAK tunnel-creation step depends; surgeons performing FLAAK are likely Ziemer laser customers.
• NIDEK: Japanese manufacturer of ophthalmic and optometric equipment, including excimer lasers and refractive surgery systems. Comparable to Neoris as a supplier of laser platforms used in corneal surgery and a potential partner or competitor in proprietary keratopigmentation workflows.
• STAAR Surgical: Manufacturer of implantable collamer lenses (ICLs) and other ophthalmic implants used to correct refractive errors. Comparable to Neoris as a developer of permanent, surgical eye-modification technologies competing for the same cosmetic-refractive patient demographic.
• Schwind eye-tech-solutions: German manufacturer of excimer and femtosecond laser systems for refractive surgery. Comparable to Neoris as a supplier of the laser platforms used in corneal and refractive procedures, including platforms that could be configured for keratopigmentation.

Broad incumbents

• Rayner Intraocular Lenses: UK-based manufacturer of intraocular lenses and ophthalmic surgical products. Comparable as an established surgical ophthalmic device vendor competing in the same refractive-correction space where Neoris positions its aesthetic keratopigmentation.
• Johnson & Johnson Vision: Global vision-care incumbent covering cataract IOLs, LASIK platforms, and contact lenses. Comparable as a broad incumbent with femtosecond/laser refractive capability (iTECH) and a contact lens portfolio that historically served consumers seeking eye color change — making it a potential adjacent competitor to Neoris's pigment-based approach.
• Alcon: One of the largest global ophthalmic medical device and surgical equipment companies, with a portfolio spanning cataract, refractive, and vision care. Comparable as a broad incumbent whose femtosecond cataract-refractive platforms (e.g., LenSx) could be adapted for cosmetic keratopigmentation.
• Bausch + Lomb: Major ophthalmic device and vision-care company covering cataract surgery, refractive lasers, and contact lenses. Comparable as a broad incumbent competing for the same surgeon channel and patient demand for eye color modification (lenses vs. permanent pigment).
• Carl Zeiss Meditec: Global ophthalmic device incumbent and manufacturer of the VISUMAX femtosecond laser platform — the same category of laser technology underlying Neoris's FLAAK procedure. Comparable as the dominant supplier of the surgical hardware Neoris-certified surgeons depend on, and a potential entrant into proprietary keratopigmentation protocols.

Emerging players

• LENSAR: US-listed company specializing in femtosecond laser systems for cataract surgery. Comparable to Neoris as a focused femtosecond laser platform player whose technology base (cornea/cataract laser surgery) overlaps directly with FLAAK's hardware stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/fferrari1000
• Facebookfacebook.com/Neoris.eyes
• LinkedInlinkedin.com/company/neoris-eyes
• Instagraminstagram.com/change.your.eye.color
• TikToktiktok.com/@changeyoureyecolor

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neoris